Author: Pogue, Jason M; Lauring, Adam S; Gandhi, Tejal N; Marshall, Vincent D; Eschenauer, Gregory A; Nagel, Jerod L; Baang, Ji Hoon; Zhou, Shiwei; Valesano, Andrew L; Petty, Lindsay A
Title: Monoclonal antibodies for early treatment of Covid-19 in a world of evolving SARS CoV-2 mutations and variants Cord-id: i9mqoks7 Document date: 2021_5_23
ID: i9mqoks7
Snippet: Monoclonal antibodies targeting the receptor binding domain (RBD) of SARS CoV-2 spike protein are important outpatient treatment options in Covid-19 to mitigate progression of disease and prevent hospitalization. The impact of different RBD mutations on efficacy of available monoclonal antibodies and processes for incorporating this impact into treatment algorithms are ill-defined. Herein, we synthesize the data surrounding the impact of key RBD mutations on efficacy of US FDA emergency use auth
Document: Monoclonal antibodies targeting the receptor binding domain (RBD) of SARS CoV-2 spike protein are important outpatient treatment options in Covid-19 to mitigate progression of disease and prevent hospitalization. The impact of different RBD mutations on efficacy of available monoclonal antibodies and processes for incorporating this impact into treatment algorithms are ill-defined. Herein, we synthesize the data surrounding the impact of key RBD mutations on efficacy of US FDA emergency use authorized monoclonal antibodies and describe our approach at Michigan Medicine at monitoring mutation frequency in circulating virus and developing an algorithm that incorporates these data into outpatient treatment pathways.
Search related documents:
Co phrase search for related documents, hyperlinks ordered by date